OIA
CRVS icon

Optimum Investment Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

Optimum Investment Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,000
Closed -$1K – 823
2022
Q2 		$1K Hold
1,000
– – ﹤0.01% 783
2022
Q1 		$2K Hold
1,000
– – ﹤0.01% 784
2021
Q4 		$2K Buy
+1,000
New +$3.88K ﹤0.01% 778

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Optimum Investment Advisors's CRVS Position: Q3 2022 in Review

Optimum Investment Advisors sold out of Corvus Pharmaceuticals (CRVS) in Q3 2022, closing a stake of 1,000 shares — an estimated $1K sold.

Optimum Investment Advisors first reported a position in CRVS in Q4 2021 and held it in 3 quarters. The position peaked at $2K in Q1 2022. 48 funds tracked by Wall St. Rank hold CRVS as of Q3 2022.

  • Optimum Investment Advisors reported no remaining Corvus Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Optimum Investment Advisors sold 1,000 Corvus Pharmaceuticals shares in Q3 2022, an estimated $1K.
  • Optimum Investment Advisors first reported a position in Corvus Pharmaceuticals in Q4 2021 and held it in 3 quarters.
  • Optimum Investment Advisors's Corvus Pharmaceuticals position peaked at $2K in Q1 2022.
  • 48 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2022.

Based on Optimum Investment Advisors's 13F filing for Q3 2022, filed 24 Oct 2022.